Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16219786 | 1.00 | EGFR (0.68) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219779 | 0.95 | EGFR (0.76) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219783 | 0.95 | EGFR (0.76) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219865 | 0.94 | EGFR (0.69) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219854 | 0.94 | EGFR (0.69) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219789 | 0.93 | EGFR (0.65) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219788 | 0.93 | EGFR (0.65) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219760 | 0.91 | EGFR (0.65) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219792 | 0.91 | EGFR (0.65) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL16219768 | 0.91 | EGFR (0.63) | EGFRERBB2ABL1PDGFRBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014177038-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-11-06 | — | — | WO | disclosed |